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The protective effect of ginsenoside Re, isolated from ginseng berry, against acute gastric mucosal lesions
was examined in rats with a single intraperitoneal injection of compound 48/80 (C48/80). Ginsenoside
Re (20 mg/kg or 100 mg/kg) was orally administered 0.5 h prior to C48/80 treatment. Ginsenoside Re
dose-dependently prevented gastric mucosal lesion development 3 h after C48/80 treatment. Increases
in the activities of myeloperoxidase (MPO; an index of neutrophil inﬁltration) and xanthine oxidase (XO)
and the content of thiobarbituric acid reactive substances (TBARS; an index of lipid peroxidation) and
decreases in the contents of hexosamine (a marker of gastric mucus) and adherent mucus, which
occurred in gastric mucosal tissues after C48/80 treatment, were signiﬁcantly attenuated by ginsenoside
Re. The elevation of Bax expression and the decrease in Bcl2 expression after C48/80 treatment were also
attenuated by ginsenoside Re. Ginsenoside Re signiﬁcantly attenuated all these changes 3 h after C48/80
treatment. These results indicate that orally administered ginsenoside Re protects against C48/80-
induced acute gastric mucosal lesions in rats, possibly through its stimulatory action on gastric mucus
synthesis and secretion, its inhibitory action on neutrophil inﬁltration, and enhanced lipid peroxidation
in the gastric mucosal tissue.
opyright  2013, The Korean Society of Ginseng, Published by Elsevier. Open access under CC BY-NC-ND license. 1. Introduction
The root of ginseng (Panax ginsengMeyer) has been traditionally
used for medicine and food. The primary physiologically-active
substances of ginseng are ginsenosides, polyacetylenes, ginseng
proteins, polysaccharides, and phenolic compounds. Ginsenosides
in particular have been identiﬁed as the principal component of
ginseng, displaying various biochemical and pharmacological
properties. A numberof researchers have studied the components of
ginseng since the late 1960s, starting with the research of Shibata
et al [1], whose research group identiﬁed the chemical structures of
ginsenosides. Ginsenoside Re (C53H90O22) is the main ingredient of
ginseng berries and roots. Notably, the amount of ginsenoside Re in
the berries was four to six times more than that in the roots [2].
Research in theareahas shownthatginsenosideReexhibitsmultiplee, Semyung University, 117 Semyun
yung Hee University, 26 Kyunghee
yj129@khu.ac.kr (Y.-J. Kim).
inseng, Published by Elsevier. Opepharmacological activities viadifferentmechanismsboth invivoand
in vitro [3e8]. However, the pharmacological effects of ginsenoside
Re on gastritis or gastric ulcer have not yet been studied.
A gastric ulcer is one of the most common diseases in the world,
which affects approximately 5e10% of people during their lives. The
therapy used to treat gastric ulcers includes control of acid secretion
aswell as the inﬂammation reversal to themucosa.Korea redginseng
can assist in the eradication of Helicobacter pylori and alleviate
H. pylori-induced halitosis [9]. A recent pharmacological investiga-
tion reports the antihistamine and anticytokine releasing effects of
ginsenoside Re isolated from the berries of Panax ginseng [7].
For the common treatment of mild gastritis, antacids in liquid or
tablet form are typically used. When antacids do not provide suf-
ﬁcient relief, H2 blocking medications, such as cimetidine, raniti-
dine, nizatidine, and famotidine, which help reduce the amount ofg-ro, Jecheon 390-711, Korea.
dae-ro, Seoul 130-711, Korea.
n access under CC BY-NC-ND license. 
J Ginseng Res 2014;38:89e9690acid are often prescribed [10]. Famotidine, the most potent H2 re-
ceptor antagonist, was used as a positive control [11].
The present study examined the protective effect of ginsenoside
Re on acute gastric mucosal lesion progression in rats treated with
compound 48/80 (C48/80). C48/80 causes degranulation of mast
cells in connective tissue with the release of histamine from the
cells, and causes the development of acute gastric mucosal lesions
with neutrophils inﬁltrating into the gastric mucosal tissue [12,13].
Injecting C48/80 is consequently suggested as a good model for
elucidating the mechanisms of clinical acute gastric lesions [14].
2. Materials and methods
2.1. Sample preparation
Ginsenoside Re was prepared according to a previously reported
method [7]. In brief, dried ginseng berries (5 kg) were ground to
powder and extracted twicewith 1 L of 95% ethyl alcohol for 2 h in a
water bath (60C). The extracts were concentrated by a vacuum
evaporator (Eyela Co., Tokyo, Japan). The lyophilized extract was
dissolved in distilled water, and was rinsed 10 times with diethyl
ether to remove unnecessary compounds. The water fraction was
suspended in distilled water and was adsorbed in a Diaion HP-20
(Mitsubishi Chemical Corporation, Tokyo, Japan) ion exchange resin
column. A 30% MeOH fraction, 50% MeOH fraction, 70% MeOH
fraction, and 100% MeOH fraction were eluted in the order named.
The 30% MeOH fraction was then subjected to an octadecylsilyl
(ODS) gel column by gradient elution with 30e100% MeOH, and
resulted in four subfractions (F1eF4). The F3 subfraction was
rechromatographed on a silica gel column with a mixture of the
solvents (CHCl3:MeOH:H2O¼ 70:30:4 v/v), and ginsenoside Re was
isolated and identiﬁed. The authenticity of ginsenoside Re was
tested by spectroscopic methods including 1H-NMR, 13C-NMR, and
fast atom bombardment-mass spectrometry (FAB-MS).
2.2. Animals and gastric mucosal lesion induction by C48/80
Male Wistar rats of 6 wk of age were purchased from Samtako
(Osan, Korea) and housed in controlled temperature (23  2C),
relative humidity (60  5%), and 12 h light/dark cycle (7:00 AMe
7:00 PM) with free access to water. The experiment was reviewed
and approved by the Animal Care and Research Ethics Committee of
the Semyung University, Jecheon, South Korea (smecae 08-12-03).
Rats were divided into ﬁve groups (n ¼ 8, respectively): normal (no
gastric lesion and administered with distilled water), gastric lesion
control (administered with distilled water), gastric lesion positive
control (administered with famotidine 4 mg/kg; Nelson Korea Co.,
Seoul, Korea), and gastric lesion administered with two levels of
ginsenoside Re (20 mg/kg and 100 mg/kg). The dosage of 20 mg/kg
of ginsenoside Re was chosen from previous published data [15].
The 100 mg/kg dosage was determined to discover the maximum
effects of ginsenoside Re. The animals were maintained with free
access to rat chow, and famotidine and ginsenoside Re were orally
administered with a stomach tube.
After 5 d of sample administration, C48/80 (0.75 mg/kg; Sigma-
Aldrich Inc., NY, USA), dissolved in saline, was intraperitoneally
injected into the rats fasted for 24 h. The normal group received a
saline injection. The animals were sacriﬁced by decapitation under
ether anesthesia 3 h after the C48/80 injection, and blood samples
were obtained from the cervical wound.
2.3. Histological Periodic acid Schiff staining
The stomachs were removed, inﬂated with 10 mL of 0.9% NaCl,
and put into 10% formalin for 10 min. The isolated stomachs werecut open along the greater curvature and washed in ice-cold saline.
The parts of the mucosa were immediately ﬁxed with 10% formalin
solution, and routinely processed for embedding in parafﬁn wax.
The sections were cut 5 mm thick and stained using the Periodic
acid Schiff (PAS) method to observe mucus secretion [16].
2.4. Determinations of gastric mucosal adherent mucus and
mucosal hexosamine
The measurement of gastric mucosal adherent mucus was
assayed using alcian blue staining [17]. In brief, the parts of the
stomach mucosa were rinsed with ice-cold 0.25M sucrose. A
50 mm2 (approximately 8 mm-diameter) portion of the glandular
region of the stomach was excised with a scalpel, and soaked in
0.1% alcian blue dissolved in 0.16M of sucrose buffered with 0.05M
sodium acetate (pH 5.8) for 2 h. The unbound dye was removed
using two successive washes with 0.25M sucrose. The dye complex
with mucus was extracted using 30% docusate sodium salt (Sigma-
Aldrich Inc., NY, USA) for 2 h. After centrifugation at 2,060 g for
10 min, the optimal density of the alcian blue solution was
measured at 620 nm, and calculated using the calibration curve.
The adherent gastric mucosal mucus was expressed as the per-
centage of the alcian blue adhering to the gastric mucosal surface of
the gastric lesion control group.
The measurement of gastric mucosal hexosamine has been used
as another indicator of gastric mucus secretion, and was assayed by
the method of Neuhaus and Letzring [18]. In brief, gastric mucosal
mucin was extracted with Triton X-100 (Sigma Co., St. Louis, MO,
USA) and then hydrolyzed with hydrochloric acid. Hexosamine
obtained from the hydrolyzed mucin was assayed using acetyla-
cetone and Ehrlich’s reagent.
2.5. Gastric mucosal enzymes and components
The parts of the gastric mucosal tissue were homogenized and
centrifuged for 10min at 9,000 g and the supernatantwas used for
malondialdehyde (MDA), myeloperoxidase (MPO), and xanthine
oxidase (XO) analyses. MDA levels of gastric mucosa were deter-
mined by the thiobarbituric acid reactive substance (TBARS) color-
imetric assay (Synergy2; BioTek Co., USA). Gastric mucosal MPO
activity was used to examine the degree of neutrophil inﬁltration
and inﬂammation. MPO activity was assayed by the method of
Suzuki et al [19], measuring the H2O2-dependent oxidation of tet-
ramethylbenzidine at 37C. Gastric mucosal XO was assayed ac-
cording to themethod of Hashimoto [20] bymeasuring the increase
in absorbance at 292nm following the formationof uric acid at 30C.
2.6. Immunoﬂuorescence analysis
The sections were cut 5 mm thick and mounted on glass slides.
The immunoﬂuorescence analysis was performed with mouse
monoclonal anti-Bax antibody and rabbit monoclonal anti-Bcl2
antibody (Santa Cruz Biotechnology, Inc., Dallas, TX, USA) and
ﬂuorescein isothiocyanate (FITC)-conjugated antimouse and anti-
rabbit IgG antibodies, respectively (Sigma Chemical Co., St Louis,
MO, USA). The nuclei were counterstained with 1 mg/mL propidium
iodide (PI; Sigma Chemical Co.). The ﬂuorescence images were
taken with a laser confocal microscope (Fluoview FV1000;
Olympus, Tokyo, Japan). The optical density was measured using
Bio1d software (Vilber Lourmat, Marne-la-Vallée Cedex, France).
2.7. Laser microdissection and protein extraction
For laser microdissection (LMD), a 10-mm thick section prepared
from the same tissue block was attached onto provided slides
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gastric tissueswere collected in a 0.5-mL tube cap using an ION LMD
(Jungwoo F&B Co.). Protein extraction was performed as previously
described [21]. Brieﬂy, the tissue fragmentswere deparafﬁnized and
boiled at 100C in TriseHCl buffer solutions of pH 8 containing 2%
sodium dodecyl sulfate (SDS). Protein concentrations were
measured using a DC Protein Assay kit (Bio-Rad, Hercules, CA, USA).
Five mL of standards and protein samples were transferred to a 96-
well plate and 25 mL of alkaline copper tartrate solution containing
Reagent S was added to each well. Then 200 mL of dilute Folin Re-
agentwas added to eachwell and the 96-well platewas incubated at
room temperature. After 15 min, the protein concentrations were
measured at 750 nmusing an enzyme-linked immunosorbent assay
(ELISA) reader (Synergy2; Biotek, Winooski, VT, USA).2.8. Western blotting analysis
Each protein was denatured with 5 sample buffer and boiled
for 5 min. Each protein was then fractionated by electrophoresis
through a 10% SDS polyacrylamide gel at 100 V for 2 h, and the
proteins were transferred onto polyvinylidene ﬂuoride (PVDF)
membranes at 100 V for 60 min. Each membrane was blocked with
TBST buffer (10mM TriseHCl, pH 7.4,150mMNaCl, 0.1% Tween-20)
containing 5% bovine serum albumin (BSA) for 1 h and then incu-
bated with primary antibodies (mouse anti-Bax and rabbit anti-
Bcl2 antibodies) in TBST buffer containing 1% BSA at 4C overnight.
The membranes were washed three times with TBST buffer and
further incubated with antimouse and anti-rabbit immunoglobulin
G (IgG) secondary antibodies conjugated with horseradish peroxi-
dase for 2 h, respectively. Each membrane was ﬁlmed with a
chemiluminescent imaging system (Fusion SL2; Vilber Lourmat),
and analyzed using Bio1d software (Vilber Lourmat).2.9. Statistical analysis
Data are presented as means  standard deviation (SD). Statis-
tical analysis was performed using one-way analysis of variance
(ANOVA) followed by Duncan’s multiple range tests. A p valueFig. 1. Histological analysis of gastric mucosa of rat stained with PAS. (A) Normal group: su
group: the PAS reactionwas reduced in surface cells (arrows). (C) Gastric lesion positive contr
Gastric lesion treated with ginsenoside Re (100 mg/kg): the PAS reaction remained in surfa<0.05 was considered to indicate statistical signiﬁcance. For all
analyses, a commercially available statistical package software was
used (SPSS version 19; SPSS Inc., Chicago, IL, USA).3. Results
3.1. Effects of ginsenoside Re on gastric mucosal lesion development
The degree of mucosal damage was examined by histological ex-
aminationwith PAS. The mucus secretionwas quantiﬁed with alcian
blue and hexosamine methods. PAS staining results are shown in
Fig. 1. The apical surface of the mucous cells in normal rats was
strongly stained with PAS (arrows in Fig. 1A) indicating intact gastric
mucosa layer. However, PAS reaction was signiﬁcantly reduced in
surface cells of the control group (arrows in Fig.1B) showing diffusive
erosion of the gastric mucosal cell layer in these rats. PAS reaction
increased in famotidine (arrows in Fig. 1C)- and ginsenoside Re (ar-
rows in Fig. 1D)-treated rats compared with the control group, sug-
gesting an increase in mucus secretion and alleviation of the erosion
in the gastric mucosal cell layer in these groups.
A signiﬁcant decrease in adherent gastric mucus content was
seen in C48/80-induced gastric lesion control rats compared with
normal rats (Table 1). Pre-administration with famotidine and
ginsenoside Re signiﬁcantly attenuated the decrease in adherent
gastric mucus content. The effects of ginsenoside Re exhibited dose
dependency. Gastric mucosal hexosamine is the best indicator of
mucin production, which is the ﬁrst line of gastric mucosal defense.
A signiﬁcant decrease in mucosal hexosamine content, like in the
adherent gastric mucus, was seen in C48/80-induced gastric lesion
control rats compared with normal rats (Table 1). Pre-administra-
tion with famotidine and ginsenoside Re signiﬁcantly attenuated
the decrease in mucosal hexosamine content. These effects of
ginsenoside Re exhibited dose dependency.3.2. Effects of ginsenoside Re on gastric mucosal lesion development
Gastric mucosal MDA content, MPO, and XO activities signiﬁ-
cantly increased in C48/80-treated control rats compared to those ofrface mucous cells (arrows) were strongly stained with PAS. (B) Gastric lesion control
ol group (famotidine, 4 mg/kg): the PAS reaction remained in surface cells (arrows). (D)
ce cells (arrows). Scale bars ¼ 100 mm. PAS, Periodic acid Schiff.
Table 1
Effects of Ginsenoside Re on Adherent Gastric Mucus and Mucosal Hexosamine
Content
Group Adherent gastric mucus
(% alcian blue/g tissue)
Mucosal hexosamine
(mg/g tissue)
Normal 100.0  4.7** 3.5  0.1**
Control 38.2  5.0* 1.6  0.2*
Famotidine1) 68.5  12.3*,** 2.5  0.4*,**
Re 202) 59.5  8.0*,** 2.0  0.2*,**
Re 1003) 64.6  9.2*,** 2.4  0.3*,**
Data are expressed as mean  standard deviation (SD; n ¼ 10).
* p < 0.05 vs. normal.
** p < 0.05 vs. control.
1) Famotidine: positive control (4 mg/kg).
2) Re 20: ginsenoside Re treated at 20 mg/kg.
3) Re 100: ginsenoside Re treated at 100 mg/kg.
J Ginseng Res 2014;38:89e9692the normal group (Table 2). The MDA content, MPO, and XO activ-
ities in the C48/80-treated control group were 3.6, 2.3, and 1.4 times
higher, respectively, than those in the normal group. Pre-adminis-
tered ginsenoside Re signiﬁcantly attenuated these parameters.
3.3. Bax and Bcl2 expressions in mucosa
Immunoﬂuorescence staining clearly showed that Bax was
expressed and limited to the cytosol of the gastric mucosal cells
(Fig. 2). Bax positive cells were found predominantly in part of the
gastric gland (arrow in Fig. 2B). The Bax staining in submucosa and
muscularis externa was very strong (arrowhead in Fig. 2B). Bax
staining decreased in famotidine (positive control, arrow in
Fig. 2C)- and ginsenoside Re (arrow in Fig. 2D)-treated rats
compared with the control group suggesting the alleviation of
apoptotic damage in the gastric mucosal cell layer in these groups.
By contrast, Bcl2 positive cells were found predominantly in part of
the normal gastric gland (arrow in Fig. 3A). Bcl2 staining in sub-
mucosa andmuscularis externawas extremely strong in the normal
group (arrowhead in Fig. 3A). Bcl2 staining became weak in both
gastric mucosa and submucosa in the control group (arrow and
arrowhead in Fig. 3B). Famotidine and ginsenoside Re attenuated
the diminishment of the Bcl2 staining in both gastric mucosa and
submucosa (arrow and arrowhead in Fig. 3C and D).
3.4. Bax and Bcl2 western blotting in mucosa
Parts of the gastric gland, submucosa, and muscularis externa
were microdissected (Fig. 4A) and the proteins were extracted. Bax
protein increased in the C48/80-treated control and decreased in
the famotidine- and ginsenoside Re-treated groups. By contrast,
Bcl2 protein decreased in the C48/80-treated control and increasedTable 2
Effects of Ginsenoside Re on Gastric Mucosal MDA Contents and MPO and XO
Activities
Group MDA (mM/mg) MPO (%) XO (mU/mg)
Normal 1.1  0.3** 100.0  9.9** 148.9  24.9**
Control 4.0  0.8* 144.9  9.0* 340.2  11.7*
Famotidine1) 1.5  0.3** 113.3  7.3*,** 251.6  18.7*,**
Re 202) 2.8  0.5*,** 135.1  10.4* 170.9  20.9**
Re 1003) 1.8  0.3*,** 116.2  8.1*,** 231.0  22.4*,**
Data expressed as mean  SD (n ¼ 10).
* p < 0.05 vs. normal.
** p < 0.05 vs. control.
MDA, malondialdehyde; MPO, myeloperoxidase; SD, standard deviation; XO,
xanthine oxidase.
1) Famotidine: positive control (4 mg/kg).
2) Re 20: ginsenoside Re treated at 20 mg/kg.
3) Re 100: ginsenoside Re treated at 100 mg/kg.in the famotidine- and ginsenoside Re-treated groups (Fig. 4B). The
ratio of Bax and Bcl2 signiﬁcantly increased in the C48/80-treated
control group compared with the normal group (Fig. 4C, p < 0.05).
The famotidine- and ginsenoside Re-treated groups showed
signiﬁcantly decreased Bax/Bcl2 ratios compared with the C48/80-
treated control (p < 0.05).
4. Discussion
Ginsenoside Re showed multiple pharmacological activities
including antidiabetic [3], antiobese [4], antioxidant, anticancer
[22], memory-enhancing [23], and anti-inﬂammatory effects [24],
and inhibitory activities on histamine release [7]. Histamine is an
organic nitrogen compound involved in regulating physiological
function in the digestive system and local immune responses. There
are four types of histamine receptors (H1eH4). Among them, the H2
receptor antagonists are used in the treatment of peptic ulcer dis-
ease, gastroesophageal reﬂux disease, and dyspepsia, as well as in
the prevention of stress ulcers [25]. Famotidine, an H2 receptor
antagonist with a thiazole nucleus, is approximately 7.5 times more
potent than ranitidine and 20 times more potent than cimetidine
on an equimolar basis [11]. Famotidine was, therefore, used as a
positive control in the present study.
Among the variety of biological activities of ginsenoside Re re-
ported in vitro and in animal models, we have noticed the anti-
histamine and anti-inﬂammatory activities [7]. In this study, we
attempted to examine the effect of ginsenoside Re on acute gastric
lesion progression induced by C48/80. The C48/80 promotes his-
tamine release [26] and causes acute gastric mucosal lesions. The
model of acute gastric mucosal lesions in rats treated once with
C48/80 has been thought to be important for clarifying the roles of
oxidative stress and inﬂammation in the pathogenesis of gastritis in
humans [27].
The results of the present study have clearly shown that gin-
senoside Re administered orally to C48/80-treated rats protects
gastric mucosal lesion progression, and its potency is similar to
famotidine. Pre-administration of ginsenoside Re ameliorated
gastric mucosal damage, mucus secretion, MDA content, MPO, and
XO activities. Mucus secretion is a crucial factor in the protection of
gastric mucosa from gastric lesions and has been regarded as an
important defensive factor in the gastric mucus barrier. A decrease
in the synthesis of mucus has been implicated in the etiology of
gastric ulcers [28]. The mucus layer protects the newly formed cells
against the damage caused by acidic pH and the proteolytic po-
tential of gastric secretions [29].
The wide distribution of adherent mucus content in the
gastrointestinal tract plays a pivotal role in cytoprotection and
repair of the gastric mucosa [30]. The results showed that severity
of erosion induced by C48/80 treatment was alleviated by ginse-
noside Re administration, and gastric mucosal damage and mucus
secretion assessed by alcian blue staining and gastric mucosal
hexosamine were dose-dependently improved by ginsenoside Re
administration.
Ohta et al [14] suggested that neutrophil inﬁltration plays a
critical role in C48/80-induced acute gastric mucosal lesion for-
mation and progression. In the present study, ginsenoside Re
normalized the increased gastric mucosal neutrophil inﬁltration
assessed by MPO activity. The level of MPO activity is directly
proportional to numbers of neutrophils, and Krawisz et al [31]
suggested that MPO activity can be used to quantitate inﬂamma-
tion. Therefore, the results of the present study suggest the sup-
pressive effect on neutrophil inﬁltration and anti-inﬂammatory
action of ginsenoside Re.
It has been shown that changes in gastric mucosal reactive ox-
ygen species (ROS) and neutrophil inﬁltration into gastric mucosal
Fig. 2. Immunoﬂuorescence analysis of Bax in the gastric mucosa of rats. The Bax positive cells were probed with anti-Bax monoclonal antibody in rat gastric mucosa (green color).
Nuclear counterstaining was performed with propidium iodide (PI). (A) Normal group: Bax staining of surface mucous cells (arrows) showed up faintly. (B) Gastric lesion control
group: Bax staining of surface mucous cells (arrows) showed up brightly. (C) Gastric lesion positive control group (famotidine, 4 mg/kg): Bax staining of surface mucous cells
(arrows) was diminished. The Bax staining of submucosa and muscularis externa (arrowheads) was identical to that carried out on the mucosa. (D) Gastric lesion treated with
ginsenoside Re (100 mg/kg): Bax staining of surface mucous cells (arrows) was diminished. The Bax staining of submucosa and muscularis externa (arrowheads) was identical to
that carried out on the mucosa. Scale bars ¼ 100 mm. * p < 0.05 vs. normal. ** p < 0.05 vs. control. (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article.)
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lesions in rats with a single C48/80 treatment [27]. XO generates
ROS during the oxidation of hypoxanthine or xanthine [32], and
Ohta et al [33] suggested that the xanthineeXO system in the
gastric mucosal tissue participates in the progression of gastricmucosal lesion. In the present study, increased MPO activitydan
index of neutrophil inﬁltrationdof the gastric lesion control group
was reduced, and ROS-related parameters such asMDA content and
XO activity were normalized by ginsenoside Re administration.
From the present study, it seems likely that administration of
Fig. 3. Immunoﬂuorescence analysis of Bcl2 in the gastric mucosa of rats. The Bcl2 positive cells were probed with anti-Bcl2 monoclonal antibody in rat gastric mucosa (green
color). Nuclear counterstaining was performed with propidium iodide (PI). (A) Normal group: Bcl2 staining of surface mucous cells (arrows) showed up brightly. (B) Gastric lesion
control group: Bcl2 staining of surface mucous cells (arrows) showed up faintly. (C) Gastric lesion positive control group (famotidine, 4 mg/kg): Bcl2 staining of surface mucous cells
(arrows) was brightened. The Bcl2 staining of submucosa and muscularis externa (arrowheads) was identical to that carried out on the mucosa. (D) Gastric lesion treated with
ginsenoside Re (100 mg/kg): Bcl2 staining of surface mucous cells (arrows) was brightened. The Bcl2 staining of submucosa and muscularis externa (arrowheads) was identical to
that carried out on the mucosa. Scale bars ¼ 100 mm. * p < 0.05 vs. normal. ** p < 0.05 vs. control. (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article.)
J Ginseng Res 2014;38:89e9694ginsenoside Re exerts a preventive effect on the progression of C48/
80-induced acute gastric mucosal lesions by protecting the gastric
mucosal barrier and tissue against the attack of ROS derived from
inﬁltrated neutrophils and the xanthineeXO system through
preservation of gastric mucus.The protein encoded by the Bcl2 gene is a regulator of pro-
grammed cell death and apoptosis. The cell survival-promoting
activity of this protein is contrary to the cell death-promoting ac-
tivity of Bax, a homologous protein that forms heterodimers with
Bcl2 and accelerates rates of cell death [34]. The expression of Bax is
Fig. 4. Representative results of Western blotting of Bax and Bcl2. The cells of interest were identiﬁed with (A, Prior to) laser microdissection, (A, Cutting) cut away with a near-IR
laser, and (A, After) dropped away from the tissue. (B) Western blotting shows changes in the expression levels of Bax and Bcl2 in the microdissected gastric tissue. (C) A histogram
of relative changes in the expression levels of the two proteins in the gastric tissues as determined by densitometric analysis. Scale bars ¼ 200 mm. * p < 0.05 vs. normal. ** p < 0.05
vs. control.
S. Lee et al / Ginsenoside Re and gastritis 95upregulated by the response of the cell to stress [35]. Bax protein
signiﬁcantly increased 3 h after hypoxiceischemic brain injury in
neonatal brain tissue [36] and it increased in gastric mucosa after
ischemiaereperfusion damage [37]. In the present results, the
predominant increase of Bax expression was discovered after C48/
80-induced acute gastritis. We have observed that the increased
Bax expression by C48/80 treatment was attenuated when ginse-
noside Re was administered. In contrast to Bax, Bcl2 expression
decreased after C48/80 induced acute gastritis and ginsenoside Re
attenuated the diminution. In Western blotting analysis, the Bax/
Bcl2 ratio result also conﬁrmed the protective effects of ginsenoside
Re on C48/80-induced acute gastritis.
In conclusion, the results of the present study indicate that
ginsenoside Re exerts a preventive effect on the progression of C48/
80-induced acute gastric mucosal lesion in rats, possibly by
inducing mucus secretion and attenuating enhanced neutrophil
inﬁltration, inﬂammation, and oxidative stress in gastric mucosa.
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